Outcome Capital argues that the orthopedic segment, and ortho in particular, remains highly attractive, as it offers investors stability, healthy multiples, and opportunities for innovation.
Published in MedTech Strategist
Author: Wendy Diller
Abstract:
Investors and entrepreneurs in recent years have gravitated away from orthopedics and medtech in general, toward splashier, hyper-growth subsectors of the life sciences, such as biotech and digital health. Outcome Capital argues that the industry—and ortho in particular—remains highly attractive, as it offers investors and entrepreneurs stability, healthy multiples, and opportunities for innovation.
Macroeconomic uncertainty, confusion surrounding the diagnostic regulatory landscape, and the continuing post-COVID-19 pandemic hangover have all contributed to a stagnant, quiet period for mergers and acquisitions in the in vitro diagnostics space in the first half of 2024.
Read MoreOutcome Capital Life Science Market Pulse June 2024 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?